Why is the Recce (ASX:RCE) share price soaring 14%?

The Recce share price is flying today on news the company has had encouraging results in its COVID-19 drug trials. Let's take a look.

| More on:
Young girl wearing a suit and tie with rocket wings looks to the sky representing the highest traded stocks today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Recce Pharmaceuticals Ltd (ASX: RCE) share price has been soaring up today. Recce shares jumped up more than 14% on news that the company has seen encouraging results in the treatment against the COVID-19 virus. The release comes on the same day that Pfizer Inc (NYSE: PFE) announced its vaccine success.

The Recce share price has risen 14.21% at the time of writing, vaulting its shares to $1.08.

What does Recce do?

Recce is involved in drug discovery and development business. It aims to commercialise a new class of synthetic antibiotics that target a wide range of diseases to address the global health challenge of antibiotic-resistant superbugs.

The group operates solely in research and development, and is located in both Australia and the United States.

COVID-19 trial success

Today the Recce share price is flying on the news that it saw encouraging results of its primary drug, Recce 327 against COVID-19. R327, a synthetic anti-infective drug, showed encouraging efficacy in an in-vitro screening assay against the virus.

FDA-approved R327 has traditionally been developed for the treatment of blood infections and sepsis. Infections that are derived from E. coli and S. aureus bacteria. However, earlier this year it was announced that the drug may also be effective against COVID-19.

As the drug showed encouraging inhibition against the virus it is now advancing to Stage 1b. This stage will be under way in near weeks.

Whilst the company is delighted by the results, it notes that preliminary and further testing must be completed before the drug can be announced as fully effective.

Recce non-executive chair John Prendergast was pleased, saying:

We're highly encouraged by the results from this study, which indicate anti-viral activity of R327 and, in particular, highlight the potential potency of our lead candidate against SARS-CoV-2 . We are interested in seeing the next stage and look forward to continuing research on the effectiveness of R327 with the team at the Doherty Institute.

Should you invest $1,000 in Tesla right now?

Before you buy Tesla shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Tesla wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

A young woman wearing a red and white striped t-shirt puts her hand to her chin and looks sideways as she wonders whether to buy NAB shares
Opinions

The pros and cons of buying Wesfarmers shares in May

Is this retail giant an appealing opportunity?

Read more »

A man looking at his laptop and thinking.
Share Market News

5 things to watch on the ASX 200 on Monday

Here's what to expect on the local market today.

Read more »

Five retirees do a conga line dance on the beach celebrating the special dividend announced by Grange Resources today
Broker Notes

Why Macquarie thinks the NZ retirement village sector could be an emerging opportunity for ASX investors

Oceania Healthcare and Summerset could quietly emerge as high-upside plays for patient ASX investors.

Read more »

Excited couple celebrating success while looking at smartphone.
Broker Notes

5 high-conviction ASX 200 shares to buy

Brokers are tipping these shares as buys. Here’s what they rate highly.

Read more »

A woman in a business suit sits at her desk with gold bars in each hand while she kisses one bar with her eyes closed. Her desk has another three gold bars stacked in front of her. symbolising the rising Northern Star share price
Gold

How this ASX All Ords gold stock turned $10,000 into $78,740 in just one year

The ASX All Ords gold miner has raced higher over the year. Let’s find out how.

Read more »

Man raising both his arms in the air with a piggy bank on his lap, symbolising a record high.
Share Market News

US-China tariff deal sparks strong week for ASX 200

Energy shares ripped 5.77% higher while the ASX 200 lifted 1.37% over the five days.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »